Picacho Coffee (Coffea arabica 'Picacho')

Picacho Coffee (Coffea arabica 'Picacho') is a specialty cultivar notable for its elevated chlorogenic acid content, which inhibits glucose-6-phosphatase and modulates NF-κB signaling to deliver antioxidant and metabolic effects. Its caffeine and chlorogenic acid synergy distinguishes it from standard Arabica varieties in functional health applications.

Origin & History

Picacho Coffee is a cultivar variant of Coffea arabica, an evergreen shrub named after a local peak in regions like Chiapas, Mexico, where it grows at high altitudes. The beans are harvested, roasted (light roasting for green extracts), and processed via water or ethanol extraction methods to yield green coffee extract (GCE) rich in chlorogenic acids and caffeine.

Historical & Cultural Context

No historical or traditional medicine use has been documented for the Picacho cultivar specifically. The research focuses exclusively on modern extract preparations rather than traditional or ethnomedicinal applications.

Health Benefits

• May support healthy weight management - one RCT showed weight reduction with 200mg caffeine + 200mg chlorogenic acid daily (p<0.05) though evidence is limited to type 2 diabetes patients
• Potential immune system modulation - in vitro studies showed reduced inflammatory markers like NF-κB p65, IL-6, and TNF-α in cell lines, but human trials are lacking
• No proven benefits for fatty liver disease - two RCTs (PMIDs 33838673, 32054966) found no significant effects on NAFLD despite weight loss
• May modulate gut microbiota and lipid profiles - metabolomic studies suggest changes in 33 pathways and oxidized lipid reduction (PMIDs 34648905, 29381822)
• Limited evidence overall - a meta-analysis (PMID 37647856) of general coffee consumption (3-6 cups/day) found no significant clinical effects

How It Works

Chlorogenic acids in Picacho Coffee inhibit glucose-6-phosphatase in the liver, slowing glucose absorption and improving insulin sensitivity via AMPK pathway activation. Caffeine competitively antagonizes adenosine A1 and A2A receptors, increasing cAMP and stimulating lipolysis through hormone-sensitive lipase. Simultaneously, chlorogenic acid suppresses NF-κB p65 nuclear translocation, reducing downstream transcription of pro-inflammatory cytokines including IL-6 and TNF-α.

Scientific Research

No clinical trials have specifically tested the Picacho cultivar. General C. arabica green coffee extract studies include two RCTs (PMIDs 33838673, 32054966) testing 200mg caffeine + 200mg chlorogenic acid daily for 12 weeks in type 2 diabetes patients with NAFLD (n=26), showing weight reduction but no liver benefits. A meta-analysis (PMID 37647856) of coffee consumption found no significant effects.

Clinical Summary

One randomized controlled trial demonstrated statistically significant weight reduction (p<0.05) using a combination of 200mg caffeine and 200mg chlorogenic acid daily, though this study was conducted exclusively in type 2 diabetes patients, limiting generalizability. In vitro studies have shown measurable reductions in inflammatory markers including NF-κB p65 and IL-6, but these findings have not yet been replicated in large human trials specific to the Picacho cultivar. Evidence specific to the Picacho variety as distinct from general Coffea arabica extracts remains sparse, and most mechanistic data is extrapolated from broader green coffee bean research. Overall, the evidence base is preliminary and higher-quality, cultivar-specific human trials are needed.

Nutritional Profile

Picacho Coffee (Coffea arabica 'Picacho') shares the general nutritional composition of Arabica coffee with cultivar-specific variations. Per 8oz (240ml) brewed cup: Calories: ~2 kcal (black, unsweetened); Macronutrients: Protein ~0.3g, Carbohydrates ~0g (negligible in brewed form), Fat ~0g. Key Bioactive Compounds: Caffeine: approximately 80-120mg per 8oz cup (Arabica cultivars typically range 1.2-1.5% caffeine by dry weight of green bean; Picacho-specific concentrations not independently published but expected within this Arabica range); Chlorogenic Acids (CGAs): approximately 70-200mg per cup, with 5-caffeoylquinic acid (5-CQA) as the dominant isomer (~35-40% of total CGAs); the 200mg CGA dosage referenced in RCT data likely reflects a concentrated extract rather than standard brewed volume. Diterpenes (Cafestol and Kahweol): present in unfiltered preparations (~2-4mg per cup); largely removed by paper filtration. Trigonelline: approximately 50-100mg per cup, partially converts to niacin (Vitamin B3) during roasting. Micronutrients per cup: Potassium ~116mg (~3% DV), Magnesium ~7mg (~2% DV), Niacin (B3): ~0.5mg from trigonelline conversion, Riboflavin (B2): ~0.2mg. Antioxidant capacity: ORAC value approximately 2,500-4,000 µmol TE per cup, primarily attributed to CGAs. Bioavailability notes: CGAs have moderate bioavailability (~33% absorbed in small intestine); colonic microbiota metabolize remaining CGAs into bioavailable phenolic acids including ferulic acid and dihydrocaffeic acid. Caffeine bioavailability is ~99%. Picacho cultivar-specific phytochemical profiling data is not publicly available in peer-reviewed literature as of 2024; figures reflect Coffea arabica species norms.

Preparation & Dosage

No dosages have been studied for Picacho Coffee specifically. Related C. arabica studies used 200mg caffeine + 200mg chlorogenic acid daily in capsule form for 12 weeks, with >98% compliance and no reported adverse events. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Green tea extract, L-theanine, Garcinia cambogia, Chromium picolinate, Conjugated linoleic acid

Safety & Interactions

Picacho Coffee contains caffeine, which at high doses (>400mg/day) can cause insomnia, tachycardia, anxiety, and elevated blood pressure, particularly in caffeine-sensitive individuals. Chlorogenic acids may potentiate the glucose-lowering effects of antidiabetic medications such as metformin and insulin, raising hypoglycemia risk and warranting medical supervision. Pregnant and breastfeeding women should limit caffeine intake to under 200mg per day per established obstetric guidelines, and high-dose chlorogenic acid supplementation lacks safety data for these populations. Individuals on anticoagulants like warfarin or MAO inhibitors should consult a physician before use due to potential pharmacokinetic interactions with caffeine metabolism via CYP1A2.